A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression
- PMID: 37976400
- DOI: 10.1097/HEP.0000000000000683
A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression
Abstract
Background and aims: HCV infection can be successfully managed with antiviral therapies; however, progression to chronic liver disease states, including NAFLD, is common. There is currently no reliable in vitro model for investigating host-viral interactions underlying the link between HCV and NAFLD; although liver organoids (LOs) show promise, they currently lack nonparenchymal cells, which are key to modeling disease progression.
Approach and results: Here, we present a novel, multicellular LO model using a coculture system of macrophages and LOs differentiated from the same human pluripotent stem cells (PSCs). The cocultured macrophages shifted toward a Kupffer-like cell type, the liver-resident macrophages present in vivo , providing a suitable model for investigating NAFLD pathogenesis. With this multicellular Kupffer-like cell-containing LO model, we found that HCV infection led to lipid accumulation in LOs by upregulating host lipogenesis, which was more marked with macrophage coculture. Reciprocally, long-term treatment of LOs with fatty acids upregulated HCV amplification and promoted inflammation and fibrosis. Notably, in our Kupffer-like cell-containing LO model, the effects of 3 drugs for NASH that have reached phase 3 clinical trials exhibited consistent results with the clinical outcomes.
Conclusions: Taken together, we introduced a multicellular LO model consisting of hepatocytes, Kupffer-like cells, and HSCs, which recapitulated host-virus intercommunication and intercellular interactions. With this novel model, we present a physiologically relevant system for the investigation of NAFLD progression in patients with HCV.
Copyright © 2023 American Association for the Study of Liver Diseases.
Comment in
-
Navigating liver disease complexity: Innovations in in vitro modeling and precision medicine.Hepatology. 2024 Jul 1;80(1):20-23. doi: 10.1097/HEP.0000000000000719. Epub 2023 Dec 13. Hepatology. 2024. PMID: 38088881 No abstract available.
References
-
- Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: A chronic problem. Hepatology. 2008;47:321–31.
-
- Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, et al. Acute hepatitis C in a contemporary US cohort: Modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474–82.
-
- Ji D, Chen G, Niu X, Zhang M, Wang C, Shao Q, et al. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open. 2021;10:100090.
-
- Prevention CfDCa. Hepatitis C Surveillance 2020. https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c.htm
-
- Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851–61.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical